Mediheal is turning a historic winning streak in South Korea into fresh momentum in the U.S. skincare market, after being named the No. 1 brand in total sales at Olive Young for two consecutive years (2024–2025), ahead of more than 3,000 competing brands. Widely described as the Korean equivalent of Ulta or Sephora, Olive Young has become a proving ground for K beauty brands with real global potential and Mediheal’s performance there is now accelerating its international expansion.
Record breaking wins at Olive Young
At the latest Olive Young Awards, Mediheal took home four major honors, underscoring its dominance across key skincare formats. The brand was awarded No. 1 in the Toner Pad category, Global Trend Best Performer for the Madecassoside Blemish Pad, Global Trend Rising for the Madecassoside Blemish Serum, and Winner in the Mask category with the Madecassoside Essential Sheet Mask.
Within this lineup, the Madecassoside Blemish Pad…
ranked No. 1 in its category for the second year in a row, while the Madecassoside Blemish Repair Serum posted an 820% year on year sales jump, cementing madecassoside as a hero ingredient for the brand. These results help explain why Mediheal has secured the No.
1 mask ranking for 15 consecutive years at Olive Young, alongside more than 3.3 billion sheet masks sold worldwide and over 32 million toner pads sold globally. From Korean bestseller to U.S. Amazon breakout The same formulas driving Mediheal’s success in Korea are now showing traction with U.S. consumers.
During the recent Black Friday and Cyber Monday period, the brand’s Retinol Collagen Eye Patch surged to No.
1 in Amazon’s “Movers & Shakers in Beauty & Personal Care” category, which spotlights products with the fastest sales gains over a 24 hour window. Since its founding in 2009, Mediheal has used toner pads, serums, and sheet masks as its core growth engines across markets…
Members-only article
Unlock the rest of this story
Join free to keep reading RetailBoss beauty coverage, industry analysis, and market intelligence.
- Full article access
- Industry analysis
- Free account
Free access. No credit card required. Your account is created after you verify your email.
Discussion
0 Comments
No comments yet
Start the conversation
Share your take on this story and help shape the discussion.
Sign in to join the discussion.